Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2006-10-03
2006-10-03
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S093480, C424S093200, C424S234100, C424S258100, C424S184100, C435S320100, C435S071100, C435S069300
Reexamination Certificate
active
07115269
ABSTRACT:
The present invention is directed to an attenuatedSalmonellacomprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuatedSalmonellacomprising the eukaryotic expression vector.
REFERENCES:
patent: 5231176 (1993-07-01), Goeddel et al.
patent: 5332658 (1994-07-01), Dyall-Smith et al.
patent: 5656488 (1997-08-01), Curtiss, III et al.
patent: 5736388 (1998-04-01), Chada et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5869057 (1999-02-01), Rock
patent: 5877159 (1999-03-01), Powell et al.
patent: 5986061 (1999-11-01), Pestka
patent: 6054570 (2000-04-01), Vogelstein et al.
patent: 6099848 (2000-08-01), Frankel et al.
patent: 6150170 (2000-11-01), Powell et al.
patent: 6365576 (2002-04-01), Carr
patent: 6682729 (2004-01-01), Powell et al.
patent: 2003/0153527 (2003-08-01), Powell et al.
patent: WO 97/08955 (1997-03-01), None
Mitcehll et al. Mol. Microbiol. 5: 1883-1888, 1991.
Feldman et al. Am. J. Respir. Cell Mol. Biol. 5: 416-423, 1991.
Bowie et al. Science 247: 1306-1310, 1990.
Houghton et al. Vaccines86, Cold-Spring Harbor Laboratory, p. 21-25, 1986.
Srinivasan et al. Biol. Reproduct. 53: 462-471, 1995.
Brown et al. J. Infect. Dis. 155: 86-92, 1987.
Yang et al. J. Immunol. 145: 2281-2285, 1990.
Tite et al. Immunology 70: 540-546, 1990.
Verma et al. Vaccine 13: 142-150, 1996.
Fouts et al. Vaccine 13: 1697-1705, 1995.
Sztein et al. J. Immunol. 155: 1697-1705, 1995, abstract.
Stocker et al. Intern. Rev. Immunol. 11: 167-178, 1994.
“An AttenuatedaroA Salmonella typhimuriumVaccine Elicits Humoral and Cellular Immunity to Cloned β-Galactosidase in Mice”, Brown et al., XP-002071286, The Journal of Infectious Diseases, vol. 155, No. 1, Jan. 1987, pp. 86-92.
“Salmonella typhimurium ΔaroA ΔaroDMutants Expressing a Foreign Recombinant Protein Induce Specific Major Histocompatibility Complex Class I-Restricted Cytotoxic T Lymphocytes in Mice”, Turner et al., XP-002071285, Infection and Immunity, December 1993, pp. 5374-5380.
“AttenuatedShigellaas a DNA Delivery Vehicle for DNA-Mediated Immunization”, Sizemore et al., Science, vol. 270, Oct. 13, 1995, pp. 299-302.
“Interaction ofSalmonella typhiStrains with Cultured Human Monocyte-Derived Marcophages”, Sizemore, et al., XP-002071319, Infection and Immunity, Jan. 1997, pp. 309-312.
International Preliminary Examination Report for PCT/EP97/06933 dated Jul. 2, 1999.
International Search Report in PCT/EP97/06933 dated Jul. 28, 1998.
“Expression inEscherichia coliand Sequence Analysis of the Listeriolysin O Determinant ofListeria monocytogenes”, Mengaud et al., Infection and Immunity, Apr. 1998, pp. 766-772.
“A Novel Bacterial Virulence Gene inListeria monocytogenesRequired for Host Cell Microfilament Interaction with Homology to the Proline-Rich Region of Vinculin”, Domann et al., The EMBO Journal vol. 11, No. 5, 1992, pp. 1981-1990.
“Gene Transfer from Bacteria to Mammalian Cells”, Courvalin et al., Comptes Rendues de L'Academie Des Sciences, vol. 318, No. 12, 1995, pp. 1207-1212.
“Oral Somatic Transgene Vaccination Using AttenuatedS. typhimurium”, Darji et al., Cell, vol. 91, Dec. 12, 1997, pp. 765-775.
Bouwer et al., “Listeriolysin O is a target of the immune response toListeria monocytogense,” J. Exp. Med., 175:1467-1471, 1992.
Ikonomidis et al., “Delivery of a viral antigen to the Class I processing and presentation pathway byListeria monocytogense,” J. Exp. Med. 180:2209-2218, 1994.
Pamer et al., “Precise prediction of a dominant class I MHC-restrict epitope ofListeria monocytogense,” Nature353:852-855, 1991.
Safley et al., “Role of listeriolysin-O (LLO) in the T lymphocyte response to infection withListeria monocytogense,” J. Immunol. 146:3604-3616, 1991.
Chakraborty Trinad
Darji Ayub
Gerstel Birgit
Guzman Carlos A.
Timmis Kenneth
Devi S.
Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
Marshall & Gerstein & Borun LLP
LandOfFree
Attenuated Salmonella strain used as a vehicle for oral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated Salmonella strain used as a vehicle for oral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated Salmonella strain used as a vehicle for oral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3689321